The company’s MI Cancer Seek is approved as a companion diagnostic for multiple cancer therapies, including MSD’s Keytruda, ...

The market is also wondering how Merck may eventually need to find a replacement for its top-selling Keytruda immunotherapy ...

Image credit: Shutterstock/Andrii Yalanskyi ... The therapy is being tested alone and in combination with MSD’s blockbuster cancer treatment Keytruda (pembrolizumab). Earlier this year, RAPT shared ...

Momentis Surgical Ltd., a leader in robotic-assisted surgical innovation, today announced the U.S. Food and Drug Administration (FDA) 510(k) clearance for its second-generation Anovo® robotic surgical ...

Keytruda in early-stage triple-negative breast cancer led to immune-related adverse effects, including severe GI issues and ...

Merck (NYSE: MRK) recently reported its Q3 results, with revenues and earnings exceeding the street estimates.

Keytruda also cleared for surgery-spanning use In another positive development for the lung cancer community, NICE has also given its blessing to NHS use of MSD's $25 billion immunotherapy ...

The top-line beat was led by its higher than anticipated sales of Covid-19 vaccine, while its recently approved respiratory syncytial virus vaccine raked in just $10 ...

It also included arms looking at belrestotug given with MSD's rival PD-1 drug Keytruda (pembrolizumab) and Keytruda alone, although, data from those arms was not ready for presentation at ESMO.

Iovance Biotherapeutics' strong Q3 earnings and promising drug pipeline suggest growth potential for risk-tolerant investors.

Bicycle Therapeutics is a biopharma company targeting unmet medical needs. Discover why BCYC stock benefits from strong ...